This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Generex Biotechnology Announces Presentation Of Early Results Showing Activity Of Cancer Vaccine In Patients With Triple Negative Breast Cancer

Stocks in this article: GNBT









WORCESTER, Mass. and TORONTO, Sept. 13, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) ( www.generex.com), announced today presentation of early results from an efficacy study of an immunotherapeutic in triple negative breast cancer patients.  The immunotherapeutic is being developed by Antigen Express, Inc. ( www.antigenexpress.com), a wholly owned subsidiary of Generex.  The results will be presented on Friday, September 14, 2012 at the 2012 Breast Cancer Symposium organized by the American Society of Clinical Oncology (ASCO) being held in San Francisco September 13 - 15.

The presentation, entitled Early Efficacy Analysis of the AE37 Vaccine in Patients with HER2 Low-Expressing and Triple Negative Breast Cancer, will be made by Dr. Elizabeth Mittendorf, who is the Principal Investigator of the ongoing Phase II trial of the immunotherapeutic AE37.  While the study showed an overall reduction of 42% in the risk of relapse in all patients of the study who received the vaccine, the reduction in the risk of relapse was 66% in patients with low expression of the HER2 oncoprotein who were classified as having triple negative breast cancer.

The immunotherapeutic being developed by Antigen Express is designed to generate an immune response specifically targeting tumor cells expressing the HER2 oncoprotein.  While this is the same target as that of the widely used drug Herceptin, the immune response elicited by AE37 is capable destroying cells expressing lower levels of HER2 that are required for sensitivity to Herceptin.  "The suggestion of the ability of AE37 to prevent recurrence in breast cancer patients is very encouraging," said Dr. Mittendorf.  "This is particularly so in patients with triple negative disease, for whom treatment options are extremely limited," she added.

Antigen Express is currently in late stage Phase II clinical development of AE37.  Based upon positive data obtained to date, the company is proceeding with plans for a pivotal Phase III trial.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs